These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9046982)

  • 21. Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls.
    Nilsson BM; Hultman CM; Wiesel FA
    Prostaglandins Leukot Essent Fatty Acids; 2006 May; 74(5):339-46. PubMed ID: 16600583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects.
    Altshuler LL; Ventura J; van Gorp WG; Green MF; Theberge DC; Mintz J
    Biol Psychiatry; 2004 Oct; 56(8):560-9. PubMed ID: 15476685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negative, positive, and disorganized symptom dimensions in schizophrenia, major depression, and bipolar disorder.
    Toomey R; Faraone SV; Simpson JC; Tsuang MT
    J Nerv Ment Dis; 1998 Aug; 186(8):470-6. PubMed ID: 9717864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study.
    Kendler KS; McGuire M; Gruenberg AM; Walsh D
    Am J Psychiatry; 1995 May; 152(5):755-64. PubMed ID: 7726316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Niacin subsensitivity is associated with functional impairment in schizophrenia.
    Messamore E
    Schizophr Res; 2012 May; 137(1-3):180-4. PubMed ID: 22445461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Test-retest stability of the oral niacin test and electrodermal activity in patients with schizophrenia.
    Nilsson BM; Hultman CM; Ekselius L
    Prostaglandins Leukot Essent Fatty Acids; 2009; 81(5-6):367-72. PubMed ID: 19864122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia.
    Smesny S; Rosburg T; Riemann S; Baur K; Rudolph N; Berger G; Sauer H
    Prostaglandins Leukot Essent Fatty Acids; 2005 Jun; 72(6):393-402. PubMed ID: 15885994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers.
    Liu SK; Chiu CH; Chang CJ; Hwang TJ; Hwu HG; Chen WJ
    Am J Psychiatry; 2002 Jun; 159(6):975-82. PubMed ID: 12042186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dysthymic schizophrenia. Reality or fiction?].
    Beguin T; Hakim C
    Ann Med Psychol (Paris); 1992 Oct; 150(8):580-2; discussion 583. PubMed ID: 1342572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia.
    Hudson C; Gotowiec A; Seeman M; Warsh J; Ross BM
    Biol Psychiatry; 1999 Aug; 46(3):401-5. PubMed ID: 10435206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schizophrenia and manic-depression: separate illnesses or a continuum?
    Lapierre YD
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S59-64. PubMed ID: 7874666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive functions in stable schizophrenia & euthymic state of bipolar disorder.
    Trivedi JK; Goel D; Sharma S; Singh AP; Sinha PK; Tandon R
    Indian J Med Res; 2007 Nov; 126(5):433-9. PubMed ID: 18160747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome.
    Martínez-Arán A; Penadés R; Vieta E; Colom F; Reinares M; Benabarre A; Salamero M; Gastó C
    Psychother Psychosom; 2002; 71(1):39-46. PubMed ID: 11740167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schizophrenia and affective disorder show different visual scanning behavior for faces: a trait versus state-based distinction?
    Loughland CM; Williams LM; Gordon E
    Biol Psychiatry; 2002 Aug; 52(4):338-48. PubMed ID: 12208641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder.
    Gray L; Scarr E; Dean B
    Psychiatry Res; 2006 Aug; 143(2-3):111-20. PubMed ID: 16831468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bipolar depression in the clinic of schizophrenia].
    Bobrov AS; Chuiurova ON; Rozhkova NIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(7):9-16. PubMed ID: 25176260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decline in diagnoses of schizophrenia in Tasmania during the period 1965-1990.
    Jones IH; Kirkby KC; Hay DA; Daniels BA; Longmore LM
    Acta Psychiatr Scand; 1997 Jan; 95(1):13-8. PubMed ID: 9051155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiology of schizophrenia, bipolar disorder, and schizoaffective disorder.
    Martin LF; Hall MH; Ross RG; Zerbe G; Freedman R; Olincy A
    Am J Psychiatry; 2007 Dec; 164(12):1900-6. PubMed ID: 18056246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of the concept of cycloid psychosis.
    Brockington I; Roper A
    Psychopathology; 1990; 23(4-6):193-5. PubMed ID: 2084769
    [No Abstract]   [Full Text] [Related]  

  • 40. P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia.
    Sánchez-Morla EM; García-Jiménez MA; Barabash A; Martínez-Vizcaíno V; Mena J; Cabranes-Díaz JA; Baca-Baldomero E; Santos JL
    Acta Psychiatr Scand; 2008 Apr; 117(4):313-8. PubMed ID: 18241306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.